Reem Karmali
A5000227859- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Cancer, Lipids, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Integrated Circuits and Semiconductor Failure Analysis
- Cancer Genomics and Diagnostics
- Nutrition and Health in Aging
- Cutaneous lymphoproliferative disorders research
- Sarcoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Multiple and Secondary Primary Cancers
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- T-cell and Retrovirus Studies
- Glioma Diagnosis and Treatment
Northwestern University
2017-2025
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2017-2025
Northwestern Memorial Hospital
2024
Midwestern University
2022-2023
Indo-American Center
2020-2022
Northwestern Medical Faculty Foundation
2020
Rush University Medical Center
2007-2019
Rush University
2008-2018
Carolinas Healthcare System
2016
Churchill Hospital
2016
Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increasingly used in patients lacking HLA-matched sibling donors (MSD). We compared outcomes after Haplo-HCT PT-Cy with MSD-HCT lymphoma, the Center for International Blood and Marrow Transplant Research registry.We evaluated 987 adult undergoing either (n = 180) or 807) following reduced-intensity conditioning regimens. The group received graft-versus-host...
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of within 24 months (POD24) from first-line immunochemotherapy or refractory to both CD20-targeting agent alkylator (double refractory), due no established standard care poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two more lines prior systemic therapy, but there consensus on its optimal timing the course...
Mantle cell lymphoma (MCL) is a B-cell characterized by cyclin D1 expression. Autologous hematopoietic transplantation (AHCT) consolidation after induction chemotherapy often used for eligible patients; however, the benefit remains uncertain in rituximab era. Herein we retrospectively assessed impact of AHCT on survival large cohort transplantation-eligible patients age 65 years or younger.We studied adults younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective...
<h3>Importance</h3> Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy autologous hematopoietic cell transplant (AHCT) is an accepted effective strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. <h3>Objective</h3> To assess outcomes in patients with PCNSL undergoing AHCT 3 most commonly used regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU),...
Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from pivotal randomized phase 3 ZUMA-7 study axicabtagene ciloleucel (axi-cel) SOC. PRO instruments were administered at baseline, day 50, 100, 150, month 9, and every months randomization until 24 or an event-free survival event. The quality life (QoL) set comprised...
To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic Hodgkin lymphoma patients destined for an autologous stem cell transplant.
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability response and prevalent toxicities remain problematic. Identifying who are at high risk disease progression, toxicity, death would inform treatment decisions. Although the cumulative illness rating scale (CIRS) been shown to correlate in malignancies, no prognostic score independently validated CART recipients. We...
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated mixed outcomes in small cohorts of patients relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI efficacy more definitively this population, we retrospectively evaluated clinical a large cohort 96 receiving failure across 15 US academic centers. Most (53%) had diffuse lymphoma, were treated axicabtagene ciloleucel (53%), early (≤180 days) (83%), and received pembrolizumab (49%) or nivolumab...
Chimeric antigen receptor (CAR) T-cell (CAR-T) immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of convergence race and social determinants health outcomes patients treated with CAR-T therapy. We examined interactions between insurance type care use in aggressive B-NHL. Adult r/r B-NHL CD19 CAR-Ts were identified 2015 2021 across 13 US academic centers. Insurance type, demographic, clinical...
Data on outcome, prognostic factors, and treatment for very elderly non-Hodgkin lymphomas (NHL) is sparse. We conducted a multicentre retrospective analysis of NHL patients ≥80 years (at diagnosis) treated between 1999 2009. Detailed characteristics were obtained including geriatric syndromes, activities daily living (ADLs), co-morbidities using the Cumulative Illness Rating Scale-Geriatrics (CIRS-G). identified 303 patients: 170 aggressive (84% B cell/16% T cell) 133 indolent (82% cell/18%...
The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 PTF, defined as progression while on upfront chemoimmunotherapy (PP), residual disease at end therapy (RD) or relapse < 6 months from (early relapse; ER). Median age was 58 years response to salvage 41.7%. Two-year OS 18.5% PP, 30.6% RD 45.5% ER. presence intermediate-high/high NCCN-IPI time PTF MYC translocation predicted 2-year 13.6% constituting ultra-high risk (UHR)...
BACKGROUND Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker poor survival and identifies high‐risk group patients with an expected 5‐year overall (OS) rate approximately 50%. Transplantation established option for relapsed FL, but its efficacy this specific ETF FL population has not been previously evaluated. METHODS This study compared autologous hematopoietic stem cell...
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers the soft tissue and lymph nodes. Clinical presentation prognosis these can be highly variable, leading to challenges diagnosis optimal management patients. Treatment often consists systemic therapy, recent studies support use targeted therapies patients with disorders. Observation ("watch wait") may sufficient select mild disease. These NCCN Guidelines Neoplasms include recommendations treatment...
Abstract Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) HIV-BL from 2008 to 2019 aiming identify prognostic factors and outcomes. With a median follow up 4.5 years, the 3-year progression-free survival (PFS) overall (OS) were 61% (95% confidence interval [CI] 55% 67%) 66% (95%CI 59% 71%), respectively, similar results both countries....
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory B-NHL; however, it remains unclear how sequence these therapies pre- and post-CAR-T. We conducted multicenter retrospective analysis describe peri-CAR-T practice patterns survival predictors CD19-directed CAR-T. Patients (n = 514) from 13 centers treated with CAR-T...
Peripheral T-cell lymphomas (PTCLs) are associated with poor prognosis when treated cytotoxic chemotherapy. We report the findings of a phase 2 study evaluating chemotherapy-free combination romidepsin plus lenalidomide as initial treatment for patients PTCL who were aged >60 years or noncandidates Treatment was initiated 10 mg/m2 IV on days 1, 8, and 15 25 mg taken orally from 1 to 21 28-day cycle up year. The primary objective overall response rate (ORR). Secondary objectives included...